Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 7, 2007 - Issue 11
Submit an article Journal homepage
146
Views
20
CrossRef citations to date
0
Altmetric
Review

Immunotherapy as treatment for Alzheimer’s disease

Cheryl A Hawkes Center for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada. [email protected]
&
JoAnne McLaurin Center for Research in Neurodegenerative Diseases, Department of Laboratory Medicine and Pathobiology, University of Toronto, 6 Queen’s Park Crescent, West Toronto, Ontario, M5S 3H2, Canada. [email protected]
Pages 1535-1548 | Published online: 09 Jan 2014

References

  • Woodard JS. Alzheimer’s disease in late adult life. Am. J. Pathol.49(6), 1157–1169 (1966).
  • Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde”. Clin. Anat.8(6), 429–431 (1995).
  • Wisniewski HM, Silverman W. Diagnostic criteria for the neuropathological assessment of Alzheimer’s disease: current status and major issues. Neurobiol. Aging18(Suppl. 4), S43–S50 (1997).
  • Sadowski M, Wisniewski T. Disease modifying approaches for Alzheimer’s pathology. Curr. Pharm. Des.13(19), 1943–1954 (2007).
  • Halliday G, Robinson SR, Shepherd C, Kril J. Alzheimer’s disease and inflammation: a review of cellular and therapeutic mechanisms. Clin. Exp. Pharmacol. Physiol.27(1–2), 1–8 (2000).
  • Jellinger KA, Attems J. Prevalence and impact of cerebrovascular pathology in Alzheimer’s disease and parkinsonism. Acta Neurol. Scand.114(1), 38–46 (2006).
  • Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral β-amyloid angiopathies: hereditary and sporadic. Brain Pathol.16(1), 30–39 (2006).
  • Zilka N, Ferencik M, Hulin I. Neuroinflammation in Alzheimer’s disease: protector or promoter? Bratisl Lek Listy107(9–10), 374–383 (2006).
  • Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev.81(2), 741–766 (2001).
  • Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science297(5580), 353–356 (2002).
  • Pericak-Vance MA, Bebout JL, Gaskell PC Jr et al. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am. J. Hum. Genet.48(6), 1034–1050 (1991).
  • Egensperger R, Kosel S, Schnabel R, Mehraein P, Graeber MB. Apolipoprotein E genotype and neuropathological phenotype in two members of a German family with chromosome 14-linked early onset Alzheimer’s disease. Acta Neuropathol. (Berl).90(3), 257–265 (1995).
  • St George-Hyslop PH. Genetic factors in the genesis of Alzheimer’s disease. Ann. NY Acad. Sci.924, 1–7 (2000).
  • Walsh DM, Klyubin I, Fadeeva JV et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature416(6880), 535–539 (2002).
  • Watson D, Castano E, Kokjohn TA et al. Physicochemical characteristics of soluble oligomeric Aβ and their pathologic role in Alzheimer’s autoantibodiesdisease. Neurol. Res.27(8), 869–881 (2005).
  • Cleary JP, Walsh DM, Hofmeister JJ et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci.8(1), 79–84 (2005).
  • Walsh DM, Selkoe DJ. Aβ oligomers – a decade of discovery. J. Neurochem.101(5), 1172–1184 (2007).
  • Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature400(6740), 173–177 (1999).
  • Buttini M, Masliah E, Barbour R et al. β-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease. J. Neurosci.25(40), 9096–9101 (2005).
  • Lemere CA, Maron R, Spooner ET et al. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. NY Acad. Sci.920, 328–331 (2000).
  • Weiner HL, Lemere CA, Maron R et al. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer’s disease. Ann. Neurol.48(4), 567–579 (2000).
  • Janus C, Pearson J, McLaurin J et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature408(6815), 979–982 (2000).
  • Morgan D, Diamond DM, Gottschall PE et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature408(6815), 982–985 (2000).
  • Wilcock DM, Gordon MN, Ugen KE et al. Number of Aβ inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol.20(11), 731–736 (2001).
  • Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Aβ1–42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging22(5), 721–727 (2001).
  • Asuni AA, Boutajangout A, Scholtzova H et al. Vaccination of Alzheimer’s model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages. Eur J. Neurosci.24(9), 2530–2542 (2006).
  • Zhou J, Fonseca MI, Kayed R et al. Novel Aβ peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer’s disease. J. Neuroinflammation2, 28 (2005).
  • Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL. Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer’s disease. Proc. Natl Acad. Sci. USA98(18), 10273–10278 (2001).
  • Lambert MP, Viola KL, Chromy BA et al. Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies. J. Neurochem.79(3), 595–605 (2001).
  • Lambert MP, Velasco PT, Chang L et al. Monoclonal antibodies that target pathological assemblies of Aβ. J. Neurochem.100(1), 23–35 (2007).
  • Klyubin I, Walsh DM, Lemere CA et al. Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo. Nat. Med.11(5), 556–561 (2005).
  • Chauhan NB, Siegel GJ. Reversal of amyloid β toxicity in Alzheimer’s disease model Tg2576 by intraventricular antiamyloid β antibody. J. Neurosci. Res.69(1), 10–23 (2002).
  • Lee HG, Zhu X, Nunomura A, Perry G, Smith MA. Amyloid-β vaccination: testing the amyloid hypothesis? heads we win, tails you lose! Am. J. Pathol.169(3), 738–739 (2006).
  • Chauhan NB. Intracerebroventricular passive immunization with anti-oligoAβ antibody in TgCRND8. J. Neurosci. Res.85(2), 451–463 (2007).
  • Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Aβ causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron45(5), 675–688 (2005).
  • Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med.6(8), 916–919 (2000).
  • Bard F, Barbour R, Cannon C et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc. Natl Acad. Sci. USA100(4), 2023–2028 (2003).
  • Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. Treatment with an amyloid-β antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer’s disease. J. Neurosci.25(26), 6213–6220 (2005).
  • Deane R, Sagare A, Hamm K et al. IgG-assisted age-dependent clearance of Alzheimer’s amyloid β peptide by the BBB neonatal Fc receptor. J. Neurosci.25(50), 11495–11503 (2005).
  • DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA98(15), 8850–8855 (2001).
  • Dodart JC, Bales KR, Gannon KS et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer’s disease model. Nat. Neurosci.5(5), 452–457 (2002).
  • Mohajeri MH, Saini K, Schultz JG, Wollmer MA, Hock C, Nitsch RM. Passive immunization against β-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer’s disease-causing mutation. J. Biol. Chem.277(36), 33012–33017 (2002).
  • Kotilinek LA, Bacskai B, Westerman M et al. Reversible memory loss in a mouse transgenic model of Alzheimer’s disease. J. Neurosci.22(15), 6331–6335 (2002).
  • Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-β immunization effectively reduces amyloid deposition in FcRγ-/- knock-out mice. J. Neurosci.23(24), 8532–8538 (2003).
  • Bacskai BJ, Kajdasz ST, Christie RH et al.. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med.7(3), 369–372 (2001).
  • Bacskai BJ, Kajdasz ST, McLellan ME et al.. Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci.22(18), 7873–7878 (2002).
  • Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc. Natl Acad. Sci. USA93(1), 452–455 (1996).
  • Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl Acad. Sci. USA94(8), 4109–4112 (1997).
  • Asami-Odaka A, Obayashi-Adachi Y, Matsumoto Y et al. Passive immunization of the Aβ42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer’s disease. Neurodegener. Dis.2(1), 36–43 (2005).
  • Schenk D. Amyloid-β immunotherapy for Alzheimer’s disease: the end of the beginning. Nat. Rev. Neurosci.3(10), 824–828 (2002).
  • Bayer AJ, Bullock R, Jones RW et al. Evaluation of the safety and immunogenicity of synthetic Aβ42(AN1792) in patients with AD. Neurology64(1), 94–101 (2005).
  • Senior K. Dosing in Phase II trial of Alzheimer’s vaccine suspended. Lancet Neurol.1(1), 3 (2002).
  • Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology61(1), 46–54 (2003).
  • Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med.9(4), 448–452 (2003).
  • Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer’s disease. Brain Pathol.14(1), 11–20 (2004).
  • Masliah E, Hansen L, Adame A et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology64(1), 129–131 (2005).
  • Bombois S, Maurage CA, Gompel M et al. Absence of β-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch. Neurol.64(4), 583–587 (2007).
  • Gilman S, Koller M, Black RS et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology64(9), 1553–1562 (2005).
  • Fox NC, Black RS, Gilman S et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology64(9), 1563–1572 (2005).
  • Hock C, Konietzko U, Papassotiropoulos A et al.. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat. Med.8(11), 1270–1275 (2002).
  • Hock C, Konietzko U, Streffer JR et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer’s disease. Neuron38(4), 547–554 (2003).
  • McLaurin J, Cecal R, Kierstead ME et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med.8(11), 1263–1269 (2002).
  • Furlan R, Brambilla E, Sanvito F et al.. Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain126(Pt 2), 285–291 (2003).
  • Buckwalter MS, Coleman BS, Buttini M et al. Increased T cell recruitment to the CNS after amyloid-β1–42 immunization in Alzheimer’s mice overproducing transforming growth factor-β1. J. Neurosci.26(44), 11437–11441 (2006).
  • Monsonego A, Imitola J, Petrovic S et al. Aβ-induced meningoencephalitis is IFN-γ-dependent and is associated with T-cell-dependent clearance of Aβ in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA103(13), 5048–5053 (2006).
  • Frenkel D, Maron R, Burt DS, Weiner HL. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest.115(9), 2423–2433 (2005).
  • Cribbs DH, Ghochikyan A, Vasilevko V et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid. Int. Immunol.15(4), 505–514 (2003).
  • Frenkel D, Balass M, Solomon B. N-terminal EFRH sequence of Alzheimer’s β-amyloid peptide represents the epitope of its anti-aggregating antibodies. J. Neuroimmunol.88(1–2), 85–90 (1998).
  • Frenkel D, Balass M, Katchalski-Katzir E, Solomon B. High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation. J. Neuroimmunol.95(1–2), 136–142 (1999).
  • Frenkel D, Katz O, Solomon B. Immunization against Alzheimer’s β-amyloid plaques via EFRH phage administration. Proc. Natl Acad. Sci. USA97(21), 11455–11459 (2000).
  • Frenkel D, Dewachter I, Van Leuven F, Solomon B. Reduction of β-amyloid plaques in brain of transgenic mouse model of Alzheimer’s disease by EFRH-phage immunization. Vaccine21(11–12), 1060–1065 (2003).
  • Dickey CA, Morgan DG, Kudchodkar S et al. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer’s disease-associated β-amyloid 1–42 peptide. DNA Cell Biol.20(11), 723–729 (2001).
  • Sergeant N, Bombois S, Ghestem A et al. Truncated β-amyloid peptide species in pre-clinical Alzheimer’s disease as new targets for the vaccination approach. J. Neurochem.85(6), 1581–1591 (2003).
  • Kutzler MA, Cao C, Bai Y et al. Mapping of immune responses following wild-type and mutant Aβ42 plasmid or peptide vaccination in different mouse haplotypes and HLA class II transgenic mice. Vaccine24(21), 4630–4639 (2006).
  • Sigurdsson EM, Knudsen E, Asuni A et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer’s disease mouse model immunized with amyloid-β derivatives. J. Neurosci.24(28), 6277–6282 (2004).
  • Levites Y, Das P, Price RW et al. Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest.116(1), 193–201 (2006).
  • Maier M, Seabrook TJ, Lazo ND et al. Short amyloid-β (Aβ) immunogens reduce cerebral Aβ load and learning deficits in an Alzheimer’s disease mouse model in the absence of an Aβ-specific cellular immune response. J. Neurosci.26(18), 4717–4728 (2006).
  • Zamora E, Handisurya A, Shafti-Keramat S et al. Papillomavirus-like particles are an effective platform for amyloid-β immunization in rabbits and transgenic mice. J. Immunol.177(4), 2662–2670 (2006).
  • Wilcock DM, DiCarlo G, Henderson D et al. Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci.23(9), 3745–3751 (2003).
  • Wilcock DM, Rojiani A, Rosenthal A et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci.24(27), 6144–6151 (2004).
  • Bussiere T, Bard F, Barbour R et al. Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance. Am. J. Pathol.165(3), 987–995 (2004).
  • Manea M, Mezo G, Hudecz F, Przybylski M. Polypeptide conjugates comprising a β-amyloid plaque-specific epitope as new vaccine structures against Alzheimer’s disease. Biopolymers76(6), 503–511 (2004).
  • Agadjanyan MG, Ghochikyan A, Petrushina I et al. Prototype Alzheimer’s disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol.174(3), 1580–1586 (2005).
  • Mamikonyan G, Necula M, Mkrtichyan M et al. Anti-Aβ1–11 antibody binds to different β-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers. J. Biol. Chem.282(31), 22376–22386 (2007).
  • Moretto N, Bolchi A, Rivetti C et al. Conformation-sensitive antibodies against alzheimer amyloid-β by immunization with a thioredoxin-constrained B-cell epitope peptide. J. Biol. Chem.282(15), 11436–11445 (2007).
  • Seabrook TJ, Jiang L, Thomas K, Lemere CA. Boosting with intranasal dendrimeric Aβ1–15 but not Aβ1–15 peptide leads to an effective immune response following a single injection of Aβ1–40/42 in APP-tg mice. J. Neuroinflammation3, 14 (2006).
  • Seabrook TJ, Thomas K, Jiang L et al. Dendrimeric Aβ1–15 is an effective immunogen in wild-type and APP-tg mice. Neurobiol. Aging28(6), 813–823 (2007).
  • Racke MM, Boone LI, Hepburn DL et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid-β. J. Neurosci.25(3), 629–636 (2005).
  • Pfeifer M, Boncristiano S, Bondolfi L et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science298(5597), 1379 (2002).
  • Wilcock DM, Rojiani A, Rosenthal A et al.. Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation1(1), 24 (2004).
  • Wilcock DM, Alamed J, Gottschall PE et al. Deglycosylated anti-amyloid-β antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci.26(20), 5340–5346 (2006).
  • Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN. Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience144(3), 950–960 (2007).
  • Burbach GJ, Vlachos A, Ghebremedhin E et al. Vessel ultrastructure in APP23 transgenic mice after passive anti-Aβ immunotherapy and subsequent intracerebral hemorrhage. Neurobiol. Aging28(2), 202–212 (2007).
  • Dickstein DL, Biron KE, Ujiie M, Pfeifer CG, Jeffries AR, Jefferies WA. Aβ peptide immunization restores BBB integrity in Alzheimer disease. FASEB J.20(3), 426–433 (2006).
  • Carty NC, Wilcock DM, Rosenthal A et al. Intracranial administration of deglycosylated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J. Neuroinflammation3, 11 (2006).
  • Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J. Neural Transm.109(5–6), 813–836 (2002).
  • Greenberg SM. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology51(3), 690–694 (1998).
  • Poduslo JF, Ramakrishnan M, Holasek SS et al. In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques. J. Neurochem.102(2), 420–433 (2007).
  • Fukuchi K, Accavitti-Loper MA, Kim HD et al. Amelioration of amyloid load by anti-Aβ single-chain antibody in Alzheimer mouse model. Biochem. Biophys. Res. Commun.344(1), 79–86 (2006).
  • Paganetti P, Calanca V, Galli C, Stefani M, Molinari M. β-site specific intrabodies to decrease and prevent generation of Alzheimer’s Aβ peptide. J. Cell Biol.168(6), 863–868 (2005).
  • Levites Y, Jansen K, Smithson LA et al. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid β, amyloid β40, and amyloid β42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J. Neurosci.26(46), 11923–11928 (2006).
  • Zhang J, Wu X, Qin C et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β-amyloid plaques in a mouse model of Alzheimer’s disease. Neurobiol. Dis.14(3), 365–379 (2003).
  • Bowers WJ, Mastrangelo MA, Stanley HA, Casey AE, Milo LJ Jr, Federoff HJ. HSV amplicon-mediated Aβ vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol. Aging26(4), 393–407 (2005).
  • Zurbriggen R, Amacker M, Kammer AR et al. Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer’s disease. J. Mol. Neurosci.27(2), 157–166 (2005).
  • Kim SH, Lee KY, Kim J, Park SM, Park BK, Jang YS. Identification of a peptide enhancing mucosal and systemic immune responses against EGFP after oral administration in mice. Mol. Cells21(2), 244–250 (2006).
  • Chackerian B, Rangel M, Hunter Z, Peabody DS. Virus and virus-like particle-based immunogens for Alzheimer’s disease induce antibody responses against amyloid-β without concomitant T cell responses. Vaccine24(37–39), 6321–6331 (2006).
  • Kim HD, Tahara K, Maxwell JA et al. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Aβ1–6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer’s disease. J. Gene Med.9(2), 88–98 (2007).
  • Schiltz JG, Salzer U, Mohajeri MH et al. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer’s disease. J. Mol. Med.82(10), 706–714 (2004).
  • Okura Y, Miyakoshi A, Kohyama K, Park IK, Staufenbiel M, Matsumoto Y. Nonviral Aβ DNA vaccine therapy against Alzheimer’s disease: long-term effects and safety. Proc. Natl Acad. Sci. USA103(25), 9619–9624 (2006).
  • He Y, Sun SH, Chen RW et al. Effects of epitopes combination and adjuvants on immune responses to anti-Alzheimer disease DNA vaccines in mice. Alzheimer Dis. Assoc. Disord.19(4), 171–177 (2005).
  • Qu B, Rosenberg RN, Li L, Boyer PJ, Johnston SA. Gene vaccination to bias the immune response to amyloid-β peptide as therapy for Alzheimer disease. Arch. Neurol.61(12), 1859–1864 (2004).
  • Qu B, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN. Aβ42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J. Neurol. Sci.244(1–2), 151–158 (2006).
  • Ghochikyan A, Vasilevko V, Petrushina I et al. Generation and characterization of the humoral immune response to DNA immunization with a chimeric β-amyloid-interleukin-4 minigene. Eur. J. Immunol.33(12), 3232–3241 (2003).
  • DaSilva K, Brown ME, Westaway D, McLaurin J. Immunization with amyloid-β using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. Neurobiol. Dis.23(2), 433–444 (2006).
  • Maier M, Seabrook TJ, Lemere CA. Developing novel immunogens for an effective, safe Alzheimer’s disease vaccine. Neurodegener. Dis.2(5), 267–272 (2005).
  • Ghochikyan A, Mkrtichyan M, Petrushina I et al. Prototype Alzheimer’s disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with Alum to Quil A adjuvant switch. Vaccine24(13), 2275–2282 (2006).
  • Ghochikyan A, Petrushina I, Lees A et al. Aβ-immunotherapy for Alzheimer’s disease using mannan-amyloid-β peptide immunoconjugates. DNA Cell Biol.25(10), 571–580 (2006).
  • Koller MF, Mohajeri MH, Huber M et al. Active immunization of mice with an Aβ–Hsp70 vaccine. Neurodegener. Dis.1(1), 20–28 (2004).
  • Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD. Intranasal immunotherapy for the treatment of Alzheimer’s disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol. Aging23(6), 991–1000 (2002).
  • Nikolic WV, Bai Y, Obregon D et al. Transcutaneous β-amyloid immunization reduces cerebral β-amyloid deposits without T cell infiltration and microhemorrhage. Proc. Natl Acad. Sci. USA104(7), 2507–2512 (2007).
  • Rosenmann H, Grigoriadis N, Karussis D et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol.63(10), 1459–1467 (2006).
  • Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M. Characterization of murine immunoglobulin G antibodies against human amyloid-β1–42. Neurosci. Lett.307(2), 101–104 (2001).
  • Town T, Vendrame M, Patel A et al. Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer’s β-amyloid1–42. J. Neuroimmunol.132(1–2), 49–59 (2002).
  • Chauhan NB, Siegel GJ. Efficacy of anti-Aβ antibody isotypes used for intracerebroventricular immunization in TgCRND8. Neurosci. Lett.375(3), 143–147 (2005).
  • Spooner ET, Desai RV, Mori C, Leverone JF, Lemere CA. The generation and characterization of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol. Vaccine21(3–4), 290–297 (2002).
  • Hara H, Monsonego A, Yuasa K et al. Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer’s disease. J. Alzheimers Dis.6(5), 483–488 (2004).
  • Mouri A, Noda Y, Hara H, Mizoguchi H, Tabira T, Nabeshima T. Oral vaccination with a viral vector containing Aβ cDNA attenuates age-related Aβ accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J.21(9), 2135–2148 (2007).
  • McLaurin J, Yang D, Yip CM, Fraser PE. Review: modulating factors in amyloid-β fibril formation. J. Struct. Biol.130(2–3), 259–270 (2000).
  • Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron43(3), 321–332 (2004).
  • Arbel M, Yacoby I, Solomon B. Inhibition of amyloid precursor protein processing by β-secretase through site-directed antibodies. Proc. Natl Acad. Sci. USA102(21), 7718–7723 (2005).
  • Lemere CA, Spooner ET, LaFrancois J et al. Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice. Neurobiol. Dis.14(1), 10–18 (2003).
  • Akiyama H, McGeer PL. Specificity of mechanisms for plaque removal after Aβ immunotherapy for Alzheimer disease. Nat. Med.10(2), 117–118; author reply 118–119 (2004).
  • DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice. Neurobiol. Aging22(6), 1007–1012 (2001).
  • Liu L, Ikonen S, Tapiola T, Tanila H, van Groen T. Fimbria–fornix lesion does not affect APP levels and amyloid deposition in the hippocampus of APP+PS1 double transgenic mice. Exp. Neurol.177(2), 565–574 (2002).
  • Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid-β peptide in APPswe transgenic mice. Neurobiol. Dis.14(1), 133–145 (2003).
  • Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O’Banion MK. Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest.117(6), 1595–1604 (2007).
  • Herndler-Brandstetter D, Cioca DP, Grubeck-Loebenstein B. Immunizations in the elderly: do they live up to their promise? Wien. Med. Wochenschr.156(5–6), 130–141 (2006).
  • Nath A, Hall E, Tuzova M et al. Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer’s disease patients and Aβ antibodies can enhance Aβ neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med.3(1), 29–39 (2003).
  • Mruthinti S, Buccafusco JJ, Hill WD et al. Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides. Neurobiol. Aging25(8), 1023–1032 (2004).
  • Mruthinti S, Schade RF, Harrell DU et al. Autoimmunity in Alzheimer’s disease as evidenced by plasma immunoreactivity against RAGE and Aβ42: complication of diabetes. Curr. Alzheimer Res.3(3), 229–235 (2006).
  • Jensen MT, Mottin MD, Cracchiolo JR, Leighty RE, Arendash GW. Lifelong immunization with human β-amyloid1–42 protects Alzheimer’s transgenic mice against cognitive impairment throughout aging. Neuroscience130(3), 667–684 (2005).
  • Chen G, Chen KS, Kobayashi D et al. Active β-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of β-amyloid. J. Neurosci.27(10), 2654–2662 (2007).
  • Arendash GW, Gordon MN, Diamond DM et al. Behavioral assessment of Alzheimer’s transgenic mice following long-term Aβ vaccination: task specificity and correlations between Aβ deposition and spatial memory. DNA Cell Biol.20(11), 737–744 (2001).
  • Austin L, Arendash GW, Gordon MN et al. Short-term β-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. Behav. Neurosci.117(3), 478–484 (2003).
  • Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM. Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem.281(51), 39413–39423 (2006).
  • Kulic L, Kurosinski P, Chen F et al. Active immunization trial in Aβ42-injected P301L tau transgenic mice. Neurobiol. Dis.22(1), 50–56 (2006).
  • Rakover I, Arbel M, Solomon B. Immunotherapy against APP β-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain Aβ levels. Neurodegener. Dis.4(5), 392–402 (2007).

Websites

  • Elan Corporation. Elan: Alzheimer’s Research (Accessed 20 July 2007) www.elan.com/research_development/Alzheimers
  • Elan Corporation. Elan Company Report, 20 October 2006 (Accessed 20 July 2007) www.elan.com/news
  • Alzheimer’s Reasearch Forum (Accessed 20 July 2007) www.alzforum.org/drg/drc/
  • ClinicalTrials.gov [online] US National Institutes of Health (Accessed 20 July 2007) www.clinicaltrials.gov
  • Acumen Pharmaceuticals Inc. Acumen: Alzheimer’s Research (Accessed 20 July 2007) www.acumenpharm.com/imm.html

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.